He addressed the topic during a May 2 first quarter earnings call, saying the company is in a phase that is “focused on portfolio transformation [and] using capital to be able to acquire technologies that are attractive to the organization,” according to Seeking Alpha.
Most recently, Zimmer Biomet signed an agreement to acquire Embody, an orthobiologics company for $155 million.
Mr. Hanson also said Zimmer Biomet is looking to diversify its portfolio.
“Looking at acquisitions, which we’ve already shown in other parts of orthopedics that are faster growth, that’s mainly in our set category for us,” he said. “Eventually [we’re ]looking to diversify outside of orthopedics [and] to diversify outside of elective procedures … And we would say most likely in the near term, we would look at smaller to midsized deals, and we would kind of quantify that to say about $1 billion in revenue or less would put us in that category.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
